Wird geladen...
Successful alectinib treatment after crizotinib‐induced interstitial lung disease
A 70‐year‐old woman with lung adenocarcinoma, harbouring anaplastic lymphoma kinase gene rearrangement, was treated with crizotinib as third‐line chemotherapy. After 2 months, crizotinib was discontinued because of the development of crizotinib‐induced interstitial lung disease (ILD). Steroid treatm...
Gespeichert in:
| Veröffentlicht in: | Respirol Case Rep |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4968663/ https://ncbi.nlm.nih.gov/pubmed/27516885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.156 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|